Comments

Gain Therapeutics

GANXNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$1.21
0.054.31%
Pre-Market: 5:44 PM EDT
15 minutes delayed
Gain Therapeutics (GANX) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$5.00
Consensus Price Target1
$8.00

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Gain Therapeutics (NASDAQ:GANX) Stock, Analyst Ratings, Price Targets, Forecasts

Gain Therapeutics Inc has a consensus price target of $8 based on the ratings of 6 analysts. The high is $10 issued by Maxim Group on September 12, 2023. The low is $5 issued by B. Riley Securities on August 19, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on July 11, 2024, July 2, 2024, and May 31, 2024, respectively. With an average price target of $8.33 between HC Wainwright & Co., there's an implied 588.71% upside for Gain Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
1
Apr
0
0
0
0
May
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Oppenheimer
Chardan Capital
Maxim Group
BTIG

1calculated from analyst ratings

Analyst Ratings for Gain Therapeutics

Buy NowGet Alert
07/11/2024Buy Now561.16%HC Wainwright & Co.
Raghuram Selvaraju
$8 → $8ReiteratesBuy → BuyGet Alert
07/02/2024Buy Now561.16%HC Wainwright & Co.
Raghuram Selvaraju
$9 → $8MaintainsBuyGet Alert
05/31/2024Buy Now643.8%HC Wainwright & Co.
Raghuram Selvaraju
$9 → $9ReiteratesBuy → BuyGet Alert
05/28/2024Buy Now643.8%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
05/15/2024Buy Now643.8%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now643.8%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
04/23/2024Buy Now643.8%Oppenheimer
Hartaj Singh
 → $9MaintainsOutperformGet Alert
04/01/2024Buy Now643.8%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now395.87%Chardan Capital
Keay Nakae
 → $6ReiteratesBuy → BuyGet Alert
12/04/2023Buy Now643.8%HC Wainwright & Co.
Raghuram Selvaraju
$10 → $9MaintainsBuyGet Alert
09/18/2023Buy Now726.45%HC Wainwright & Co.
Raghuram Selvaraju
 → $10ReiteratesBuy → BuyGet Alert
09/12/2023Buy Now726.45%Maxim Group
Jason McCarthy
 → $10Initiates → BuyGet Alert
08/31/2023Buy Now726.45%HC Wainwright & Co.
Raghuram Selvaraju
 → $10ReiteratesBuy → BuyGet Alert
08/14/2023Buy Now395.87%Chardan Capital
Keay Nakae
 → $6ReiteratesBuy → BuyGet Alert
08/14/2023Buy Now726.45%HC Wainwright & Co.
Raghuram Selvaraju
 → $10ReiteratesBuy → BuyGet Alert
06/12/2023Buy Now726.45%Oppenheimer
Hartaj Singh
 → $10ReiteratesOutperform → OutperformGet Alert
05/15/2023Buy Now726.45%HC Wainwright & Co.
Raghuram Selvaraju
 → $10ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now395.87%Chardan Capital
Keay Nakae
$5.75 → $6MaintainsBuyGet Alert
05/01/2023Buy Now726.45%HC Wainwright & Co.
Raghuram Selvaraju
 → $10Reiterates → BuyGet Alert
03/27/2023Buy Now375.21%Chardan Capital
Keay Nakae
$4 → $5.75MaintainsBuyGet Alert
12/09/2022Buy Now230.58%Chardan Capital
Keay Nakae
 → $4Initiates → BuyGet Alert
11/25/2022Buy Now726.45%Oppenheimer
Hartaj Singh
$30 → $10MaintainsOutperformGet Alert
11/14/2022Buy Now726.45%HC Wainwright & Co.
Raghuram Selvaraju
$12 → $10MaintainsBuyGet Alert
11/14/2022Buy Now726.45%BTIG
Thomas Shrader
$30 → $10MaintainsBuyGet Alert
08/19/2022Buy Now313.22%B. Riley Securities
Mayank Mamtani
$11 → $5DowngradeBuy → NeutralGet Alert
03/29/2022Buy Now1222.31%B. Riley Securities
Mayank Mamtani
$21 → $16MaintainsBuyGet Alert
03/29/2022Buy Now891.74%HC Wainwright & Co.
Raghuram Selvaraju
 → $12Initiates → BuyGet Alert
11/03/2021Buy Now1635.54%B. Riley Securities
Mayank Mamtani
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for Gain Therapeutics (GANX) stock?

A

The latest price target for Gain Therapeutics (NASDAQ:GANX) was reported by HC Wainwright & Co. on July 11, 2024. The analyst firm set a price target for $8.00 expecting GANX to rise to within 12 months (a possible 561.16% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Gain Therapeutics (GANX)?

A

The latest analyst rating for Gain Therapeutics (NASDAQ:GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Gain Therapeutics (GANX)?

A

There is no last upgrade for Gain Therapeutics

Q

When was the last downgrade for Gain Therapeutics (GANX)?

A

The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.

Q

Is the Analyst Rating Gain Therapeutics (GANX) correct?

A

While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $8.00 to $8.00. The current price Gain Therapeutics (GANX) is trading at is $1.21, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch